Market Overview - The biopharmaceutical sector increased by 1.27% on February 3, with Wanzhe Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4067.74, up 1.29%, while the Shenzhen Component Index closed at 14127.1, up 2.19% [1] Stock Performance - Wanzhe Co., Ltd. (000534) closed at 30.65, with a rise of 10.01% and a trading volume of 313,500 shares, amounting to a transaction value of 921 million yuan [1] - Other notable performers included ST Weiming (002581) with a 5.01% increase, closing at 7.55, and Nearshore Protein (688137) with a 4.84% increase, closing at 44.20 [1] Capital Flow - The biopharmaceutical sector experienced a net outflow of 255 million yuan from institutional investors and 153 million yuan from retail investors, while retail investors saw a net inflow of 408 million yuan [2] - The capital flow for individual stocks showed that Wanzhe Co., Ltd. had a net outflow of 50.83 million yuan from institutional investors, while retail investors contributed a net inflow of 15.59 million yuan [3] Individual Stock Analysis - Eurolin Biotech (688319) had a net inflow of 21.61 million yuan from institutional investors, while ST Weiming (002581) saw a significant net inflow of 13.51 million yuan [3] - Conversely, major outflows were noted in Wanzhe Co., Ltd. and other stocks, indicating varied investor sentiment across the sector [3]

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

证券日报网讯2月2日，近岸蛋白发布公告称，截至2026年1月31日，公司暂未开展股票回购，公司后续 将根据市场情况择机实施本次回购计划。 ...

证券代码：688137 证券简称：近岸蛋白 公告编号：2026-003 苏州近岸蛋白质科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2024 年 9 月 26 日召开第二届董事会第六次临时会议，并于 2024 年 10 月 15 日召开 2024 年第三次临时股东大会，审议通过了《关于稳定股价措施暨以 集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证券 交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票。回购股份将用于依法注销、减少注册资本，回购价格不超过 30.68 元/股（含）， 回购资金总额不低于人民币 1,000 万元（含），不超过人民币 2,000 万元（含）， 回购期限自公司股东大会审议通过本次回购方案之日起 12 个月内。具体内容详见 公司于 2024 年 9 月 28 日在上海证券交易所网站（www.sse.com.cn）披露的《苏 州近岸蛋白质科技股份有限公司关于稳定股价措施暨以集中竞价方式回 ...

Group 1 - The company forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -85 million yuan and -66 million yuan [2] - The forecasted net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be between -84 million yuan and -65 million yuan [3] - The financial data in this performance forecast has not been audited by a registered accountant [4] Group 2 - In the same period last year, the total profit was -54.2183 million yuan, with a net profit attributable to shareholders of the parent company at -54.4163 million yuan, and a net profit after deducting non-recurring gains and losses at -71.7486 million yuan [5] - The earnings per share for the previous year was -0.78 yuan per share [6] Group 3 - The main reasons for the performance changes include an increase in revenue from the main business due to the continuous enrichment of the product line and the development of new business [6] - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages [6] - The company has expanded its marketing team and enhanced brand marketing efforts, leading to an increase in sales expenses [6] - A reduction in government subsidies compared to the previous year has been noted, impacting other income [7]

格隆汇1月30日丨近岸蛋白(688137.SH)公布，预计2025年年度实现归属于母公司所有者的净利 润-8,500.00万元到-6,600.00万元。实现归属于母公司所有者的扣除非经常性损益的净利润-8,400.00万元 至-6,500.00万元。 ...

每经AI快讯，近岸蛋白(688137)1月30日发布业绩预告，预计2025年度实现归属于母公司所有者的净利 润亏损8500万元到6600万元，上年同期归属于母公司所有者的净利润亏损5441.63万元。报告期内虽然 主营业务收入实现增长，但研发费用、销售费用增加，同时政府补助金额较上年同期减少。 ...

Financial Performance - The company expects a net profit attributable to shareholders of the parent company to be between -85 million yuan and -66 million yuan for the year 2025[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -84 million yuan and -65 million yuan[2]. - In the same period last year, the net profit attributable to shareholders was -54.42 million yuan, indicating a decline in performance year-over-year[3]. Research and Development - The company has increased its R&D investment in areas such as RNA drugs, antibody drugs, gene and cell therapy, organoids, and synthetic biology to strengthen its technological advantages[3]. - The company emphasizes its commitment to innovation and market expansion as part of its long-term growth strategy[3]. Marketing and Sales - Sales expenses have increased as the company expands its marketing team and enhances brand marketing efforts to capture more market share[4]. Government Subsidies and Income - The company has experienced a decrease in government subsidies compared to the same period last year, impacting other income[4]. Tax and Financial Reporting - The company has adjusted the value of deferred tax assets based on a cautious principle, leading to an increase in deferred tax expenses[4]. - The financial data provided is preliminary and has not been audited by registered accountants, highlighting the need for caution among investors[5]. - The final audited financial data will be disclosed in the 2025 annual report, and investors are advised to be aware of investment risks[6].

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

重组蛋白板块领跌，下跌1.42%，其中百普赛斯下跌7.3%，近岸蛋白下跌2.81%，海特生物下跌2.16%， 三生国健跌超3%。（AI生成） ...